Sign inJoin waitlistJoin the waitlist

DV

Donna Vickery

Psychologist

Credentials: ·

Research

Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
The Lancet Oncology · 2023 · 81 citations
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
The Lancet Oncology · 2025 · 29 citations
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3…
The Lancet Oncology · 2025 · 12 citations

RP
Rodolfo Perini
4 papers
Toni Choueiri
3 papers
Anishka D'Souza
2 papers
David McDermott
2 papers
EA
Edward Arrowsmith
2 papers
EH
Elisabeth Heath
2 papers
Jaime Merchan
2 papers
MM
Marc Michaelson
2 papers
Robert Figlin
2 papers
Scott Tykodi
2 papers
TB
Todd Bauer
2 papers
AR
Ananya Roy
1 paper